MacroGenics reported $-65.25M in EBIT for its fiscal quarter ending in June of 2026.





Ebit Change Date
AbbVie USD 6.88B 156M Sep/2026
Amgen USD 4.61B 777M Jun/2026
AstraZeneca USD 4.66B 1.5B Sep/2026
Biogen USD 419.5M 663.3M Sep/2026
Bristol-Myers Squibb USD 255M 44M Sep/2026
Daiichi Sankyo JPY 108.7B 23.6B Sep/2026
Eli Lilly USD 13.09B 635M Sep/2026
Genmab DKK 407M 221M Jun/2026
Geron USD -236K 10.55M Mar/2026
Gilead Sciences USD 3.85B 1.17B Jun/2026
J&J USD 6.47B 1B Sep/2026
Karyopharm Therapeutics USD -26.76M 8.92M Mar/2026
MacroGenics USD -65.25M 33.36M Jun/2026
Merck USD 7.33B 6.49B Sep/2026
Pfizer USD -180M 5.16B Jun/2026
Puma Biotechnology USD -2.2M 11.41M Jun/2024
Regeneron Pharmaceuticals USD 1.42B 675.7M Jun/2026
Roche Holding CHF 11.46B 1.91B Jun/2026
Xencor USD -36.6M 41.26M Jun/2026